AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06437886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: opioid-sparing protocol
Description: Patients in the OSA group was administrated with 0.5 to 1 mcg·kg-1 sufentanil and received PIFB combined with RSB after anesthetic induction. Patients in the control group were recommended to receive 2 to 3 mcg·kg-1 opioid-based sufentanil. PIFB was conducted at the T2 to T5 levels under ultrasound guidance. Each side received 20 ml 0.3% ropivacaine containing 2.5 mg dexamethasone. Bilateral RSB was conducted after the PIFB and the needle was inserted into the plane between the rectus abdominal muscle and its posterior sheath using an in-plane approach. After verifying needle placement, 15 ml 0.3% ropivacaine containing 2.5 mg dexamethasone was delivered to each side. In the control group, patients received no procedure and were administrated with traditional anesthetic protocol. Patients received continuous intravenous sufentanil (50 to 100 mg) and tropisetron (5 to 10 mg) at 2 ml·h-1 for the first 48 hours after surgery.
Study NCT05864131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lying
Description: After the urethral catheter is inserted, the participant lies on an examination table lined with paper towels and diapers.
Study NCT05864131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holding
Description: Holding is performed as a non-pharmacological intervention to relieve pain in children during cystometry. After the urethral catheter is inserted, the participant's parent sits in the chair, placing a paper towel and diaper on their lap. The researcher lifts the participant by the shoulder and puts them on their parent's lap, and the parent holds the participant in their arms.
Study NCT05543018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electroretinogram
Description: Retinal function assessment using electroretinogram
Study NCT05543018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy operation
Description: Vitrectomy operation to treat retinal detachment
Study NCT06360081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib
Study NCT04580277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Description: Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks
Study NCT05079633 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Homologous boost schedule
Description: 1st dose mRNA 1273 , 2nd dose mRNA 1273
Study NCT05079633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heterologous boost schedule
Description: 1st dose mRNA 1273 , 2nd dose MVC COV1901
Study NCT05162469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1909 injection
Description: SHR-1909 for intravenous injection;Strength:6ml:0.3g/vial. Dose escalation (non randomized, 6 dose-levels); Dose-expansion and efficacy-expansion(non-randomized,1-3 dose-level(s)).
Study NCT04327115 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control strategy
Description: Patients included in the control group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams.
Study NCT04327115 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intervention strategy
Description: Patients included in the intervention group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams.~They will also get a physical activity program realized with a nurse or a nursing assistant, twice a day (morning and evening) for 5 days. The intervention consists of physical support with mimed instructions, the nature of which depends on the falling risk of the participant :~* High falling risk : out of bed exercise (on a chair for at least 30 min)~* Mild falling risk : out of bed exercise + in front of chair (The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes, on both feet or one foot)~* Low falling risk : out of bed exercise + in front of chair + FTSS exercise (The participant performs a transfer activity of sitting to standing repeated 5 times, with physical assistance or not)
Study NCT04522193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glycemic Holter
Description: Continuous glycaemia monitoring,
Study NCT04522193 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gastric emptying scintigraphy
Description: Fasting administration of a Technecium-labelled milk bottle and quantification of the remaining radioactivity by a camera every 30 minutes for 4 hours.
Study NCT04522193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter ECG
Description: continuous cardiac monitoring
Study NCT04834375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weight-based dexamethasone dose
Description: Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure
Study NCT05257915 — intervention group
Intervention type: DRUG
Intervention: Perampanel
Description: For patients ≥12 years old, the initial dose is 2 mg/d, and according to the clinical response and tolerance of the patient, the dose is increased to the minimum clinically effective dose in increments of 2 mg, and the interval between dose increases is not less than 2 weeks.~For patients \<12 years, according to the actual clinical situation, the initial dose and addition plan are judged by the investigator.
Study NCT05569915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Expressive Writing
Description: Participants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days.
Study NCT05569915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Expressive Writing
Description: Participants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days.
Study NCT05569915 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies.
Study NCT05705960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chestnut
Description: Daily consumption of roasted chestnut (150g) for 14 days
Study NCT05071794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Antiemetic effect of propofol
Study NCT05071794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Description: Placebo
Study NCT06028893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart rhythm measurements with FibriCheck®
Description: Measurements are performed twice daily, starting 4 weeks before a pulmonary vein isolation procedure (PVI) and ending 4 weeks after the PVI.
Study NCT06028893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart rhythm measurements with Kardia Mobile®
Description: Measurements are performed immediately before and after every FibriCheck® measurement.
Study NCT05543343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose or normal dose staphylococcus albicans
Description: 8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily
Study NCT05301426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching of the hamstring muscles.
Description: Passive stretching of the hamstring muscles.
Study NCT05301426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural slippage of the sciatic nerve.
Description: Neurodynamic technique on the sciatic nerve.
Study NCT05301426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive upper limb mobilisations.
Description: Passive mobilisations performed on the upper limbs used as a placebo.
Study NCT05543343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 placebo tablets 3 times daily
Study NCT05102617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoSure Pro Device
Description: This device will be used for up to 4 treatments over the designated areas.
Study NCT05102617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoSure Device
Description: This device will be used for up to 4 treatments over the designated areas.
Study NCT04784390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Binocular video games
Description: Patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.
Study NCT04784390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching of the sound eye
Description: Patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
Study NCT06493396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid-free Analgesics
Description: opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
Study NCT06493396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid group
Description: Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
Study NCT06207981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction chemotherapy (mDCF)
Description: Induction chemotherapy consists of mDCF administered every 2 weeks:~* Docetaxel (40 mg/m², day 1),~* Cisplatin (40 mg/m², day 1)~* 5-FU (1200 mg/m²/day IV for 2 days)
Study NCT05102617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Cosmeceuticals
Description: Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.
Study NCT04801888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
Study NCT04801888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
Study NCT05067920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Levels of SARS-COV-2 antibodies
Description: Study of the SARS-COV-2 antibodies of COVID-19 IgM ( day 5th and 14th) and IgG ( day 14th and 28th)
Study NCT05067920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: rRT-PCR SARS-Cov-2
Description: Real time RT-PCR for COVID-19 diagnosis at day 5th,14th and 28th
Study NCT05067920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hematological and immunological biomarkers
Description: Laboratory data measure at day 5th,14th and 28th: Hemogram, cytokine levels, ratio of CD4 + / CD8 + lymphocytes, and levels of dehydrogenase lactate, ferritin, D-dimer.
Study NCT05067920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mitochondrial DNA
Description: One time quantification mitochondrial DNA haplogroup.
Study NCT05067920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 Viral Culturing
Description: Probability of isolating SARS-Cov-2 in cell culture related to CT value above 32.
Study NCT05067920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sequencing COVID-19
Description: Sequencing viral protein spike (S) COVID-19 related to CT value below 15.
Study NCT06207981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant chemotherapy (Capecitabin + Mitomycin-C)
Description: Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given
Study NCT06207981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy (Capecitabin + Mitomycin-C)
Description: Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given
Study NCT06207981 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~* 49.5 Gy (5 x 1.65 Gy/week) to the pelvis~* 60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes
Study NCT06207981 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~* 49.5 Gy (5 x 1.65 Gy/week) to the pelvis~* 60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes
Study NCT05551676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transforaminal group
Description: Epidural steroid injection will be applied with transforaminal approach accompanied by fluoroscopy.
Study NCT05551676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral parasagittal group
Description: Epidural steroid injection will be applied with lateral parasagittal approach accompanied by scopy.
Study NCT05351723 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise + cognitive training + education
Description: The research team will record videos for the Intervention group. The intervention procedure includes 3 sections: (1) 50 min of physical exercise, (2) 20 min of break time or lecture on dementia and lifestyle habits, and (3) 50 min of cognitive training. Investigators will be recruited from the National Geriatrics Hospital and trained the technicians for 1 week.~Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~Technicians will record every training session, monitor participants' health, and ensure that those in the intervention group do the exercises correctly.~We will evaluate the participants in the group after 3 months and after 6 months of intervention.
Study NCT05351723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + cognitive training + education
Description: The research team will record videos for the Intervention group. The intervention procedure includes 3 sections: (1) 50 min of physical exercise, (2) 20 min of break time or lecture on dementia and lifestyle habits, and (3) 50 min of cognitive training. Investigators will be recruited from the National Geriatrics Hospital and trained the technicians for 1 week.~Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~Technicians will record every training session, monitor participants' health, and ensure that those in the intervention group do the exercises correctly.~We will evaluate the participants in the group after 3 months and after 6 months of intervention.
Study NCT06509581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: Vitamin E will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
Study NCT06509581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: placebo will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
Study NCT05982275 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CARTemis-1
Description: A dose escalation design will be applied in successive patient cohorts until identification of Dose Limiting Toxicity (maximum dose: 6x10\^6 CAR-T/kg divided over 2 days).
Study NCT05628051 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasonographic measurement of carotid artery corrected flow time (FTc)
Description: Ultrasonic measurement of carotid corrected blood flow time: 1. Patient's head turned to the left 30°. Firstly, the 6.0 \~ 13.0MHz linear probe was placed longitudinally on the maternal neck, and the probe marker was oriented towards the maternal head. Real-time B-ultrasound images of the long axis of the right common carotid artery were obtained from the lower margin of the thyroid cartilage. Then, the probe was placed in the center of the carotid lumen, about 2cm from the bifurcation of the carotid artery, to obtain the arterial pulse Doppler flow spectrum and store the carotid flow waveform. 2. Using the caliper function of the ultrasonic instrument, carotid flow time (FT) was obtained by measuring the interval between the systolic ascending stage and the restroke notch. Wodey (W) formula to calculate FTc. FTc= FT+\[1.29× (HR-60)
Study NCT05999526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reconnection to mechanical ventilation for 1 hour
Description: As soon as the success of the spontaneous breathing trial is confirmed, the participant will be kept on the mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.
Study NCT05999526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct extubation
Description: The participant will be extubated immediately after the spontaneous breathing trial.
Study NCT05655143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Participants will undergo a 4-week balance training protocol modified from that described previously.~Participants will undergo supervised exercise three times per week for approximately 30 minutes per session. The exercise consists of single-leg balance training, hop to stabilization, and hop to stabilization plus reaching activities as presented in Figure 1. Particularly, the levels of difficulty will be progressed with visual conditions (eyes open and eyes closed), time (sec), and base of support (floor and foam pad) while hopping distance (inches) for single-leg and hopping activities, respectively. These activities will be progressed in difficulty as participants become proficient at the task.
Study NCT06502509 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Kombucha tea (Brand name E-Ben Organic Kombucha Lemon)
Description: Commercial lemon kombucha tea (Brand:E-Ben Organic Kombucha Lemon), which will be given to participants in opaque bottles for 8 weeks.
Study NCT06453603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: Receive pes anserinus PRP injection
Study NCT05318599 — intervention group
Intervention type: DEVICE
Intervention: Lung auscultation
Description: Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).
Study NCT05318599 — intervention group
Intervention type: DEVICE
Intervention: Lung ultrasound
Description: Lung ultrasonography
Study NCT05318599 — intervention group
Intervention type: OTHER
Intervention: Quality of Life's questionnaires
Description: Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)
Study NCT05318599 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary functional tests
Description: Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
Study NCT05396235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-3921
Description: Solution for infusion; Intravenous (IV)
Study NCT06453603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid injection
Description: Receive pes anserinus corticosteroid injection
Study NCT06235788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group ICEMS verbal feedback with pause group
Description: While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down and reflecting for 22 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.